This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2005.06.073v1 46/9/1677    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carrozza, J. P. Search for Related Content PubMed PubMed Citation Articles by Carrozza, J. P., Jr

CLINICAL RESEARCH

Randomized Evaluation of the TriActiv Balloon-Protection Flush and Extraction System for the Treatment of Saphenous Vein Graft Disease

Joseph P. Carrozza, Jr, MD, FACC^_*,_*, Michael Mumma, MD, FACC, Jeffrey A. Breall, MD, PhD, FACC, Aland Fernandez, MD, FACC, Eugene Heyman, PhD^||, Christopher Metzger, MD, FACC^¶ for the PRIDE Study Investigators

^_* Section of Interventional Cardiology-Beth Israel Deaconess Medical Center, Boston, Massachusetts USA
Sarasota Memorial Hospital, Sarasota, Florida USA
Krannert Institute of Cardiology, Indiana University of Medicine, Indianapolis, Indiana USA
Morton Plant Hospital, Clearwater Cardiovascular & Interventional Consultants, Clearwater, Florida USA
^|| Montgomery Village, Maryland USA
^¶ Wellmont Holston Valley Medical Center, Kingsport, Tennessee USA

Manuscript received February 28, 2005; revised manuscript received June 17, 2005, accepted June 21, 2005.

^_* Reprint requests and correspondence: Dr. Joseph P. Carrozza, Jr., Section of Interventional Cardiology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215 (Email: jcarrozz{at}bidmc.harvard.edu).

OBJECTIVES: The Protection During Saphenous Vein Graft Intervention to Prevent Distal Embolization (PRIDE) study compared outcomes with the TriActiv System (Kensey Nash Corp., Exton, Pennsylvania), a balloon-protection flush and extraction device, with an embolic protection group during treatment of saphenous venous grafts (SVGs).

BACKGROUND: Treatment of SVGs with embolic protection reduces adverse cardiac events.

METHODS: We conducted a prospective trial randomizing 631 patients with coronary ischemia and lesions in SVGs to embolic protection with the TriActiv System or control group (Guardwire System [Medtronic AVE, Santa Rosa, California] or Filterwire EX [Boston Scientific Corp., Maple Grove, Minnesota]).

RESULTS: The incidence of major adverse cardiac events at 30 days was 11.2% for the TriActiv group and 10.1% for the control group (relative risk = 1.1%; 95% confidence interval 0.67 to 1.76; p = 0.65; p = 0.02 for non-inferiority). Safety and efficacy end points were similar between groups except that patients randomized to the TriActiv System had more hemorrhagic complications (10.9% vs. 5.4%; p = 0.01).

CONCLUSIONS: The TriActiv System was not inferior to approved embolic protection devices for the treatment of diseased SVGs.

Abbreviations and Acronyms   FIRE = FilterWire EX Randomized Evaluation   MACE = major adverse cardiac events   MI = myocardial infarction   PCI = percutaneous coronary intervention   PRIDE = Protection During Saphenous Vein Graft Intervention to Prevent Distal Embolization trial   SAFER = Saphenous Vein Graft Angioplasty Free of Emboli, Randomized study   SVG = saphenous vein/venous graft   TIMI = Thrombolysis In Myocardial Infarction   TLR = target lesion revascularization   TVR = target vessel revascularization

This article has been cited by other articles:

				G. Heusch, P. Kleinbongard, D. Bose, B. Levkau, M. Haude, R. Schulz, and R. Erbel Coronary Microembolization: From Bedside to Bench and Back to Bedside Circulation, November 3, 2009; 120(18): 1822 - 1836. [Abstract] [Full Text] [PDF]

				E. R. Bates Aspirating and Filtering Atherothrombotic Debris During Percutaneous Coronary Intervention J. Am. Coll. Cardiol. Intv., June 1, 2008; 1(3): 265 - 267. [Full Text] [PDF]

				A. J. Kirtane, E. R. Heyman, C. Metzger, J. A. Breall, and J. P. Carrozza Jr Correlates of Adverse Events During Saphenous Vein Graft Intervention With Distal Embolic Protection: A PRIDE Substudy J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 186 - 191. [Abstract] [Full Text] [PDF]

				A. Coolong, D. S. Baim, R. E. Kuntz, A. J. O'Malley, S. Marulkar, D. E. Cutlip, J. J. Popma, and L. Mauri Saphenous Vein Graft Stenting and Major Adverse Cardiac Events: A Predictive Model Derived From a Pooled Analysis of 3958 Patients Circulation, February 12, 2008; 117(6): 790 - 797. [Abstract] [Full Text] [PDF]

				L. Mauri, D. Cox, J. Hermiller, J. Massaro, J. Wahr, S. W. Tay, M. Jonas, J. J. Popma, J. Pavliska, D. Wahr, et al. The PROXIMAL Trial: Proximal Protection During Saphenous Vein Graft Intervention Using the Proxis Embolic Protection System: A Randomized, Prospective, Multicenter Clinical Trial J. Am. Coll. Cardiol., October 9, 2007; 50(15): 1442 - 1449. [Abstract] [Full Text] [PDF]

				L. Mauri, C. Rogers, and D. S. Baim Devices for Distal Protection During Percutaneous Coronary Revascularization Circulation, June 6, 2006; 113(22): 2651 - 2656. [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1689 - 1706. [Full Text] [PDF]